RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
 Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Research Article
Latest Research Channel

subscribe to Latest Research newsletter
Latest Research

   EMAIL   |   PRINT
Probiotics unsafe for severe acute pancreatitis patient's due to its increased mortality.

Feb 14, 2008 - 7:00:00 AM
The authors say: Our findings show that probiotics should not be administered routinely in patients with predicted severe acute pancreatitis, and that the particular composition used here should be banned for the present indication. Whether other combinations of strains might have resulted in different results is debatable, but, until the underlying mechanism is actually revealed, administration of probiotics in patients with predicted severe acute pancreatitis must be regarded as unsafe.

Key Points of this article
Probiotics are associated with an increased mortality in patients with severe acute pancreatitis
Around a fifth of patients with severe pancreatitis disease have necrotising pancreatitis, which has a 10-30% mortality rate largely due to infectious complications.
probiotics should not be administered routinely in patients with predicted severe acute pancreatitis,
 
Main results
probiotics should not be administered routinely in patients with predicted severe acute pancreatitis, and that the particular composition used here should be banned for the present indication. until the underlying mechanism is actually revealed, administration of probiotics in patients with predicted severe acute pancreatitis must be regarded as unsafe.
probiotics in patients with severe pancreatitis
probiotics in patients with predicted severe acute pancreatitis must be regarded as unsafe.
[RxPG] Probiotics are associated with an increased mortality in patients with severe acute pancreatitis, and do not reduce the risk of infectious complications in these patients. These are the conclusions of authors of an Article published early Online and in an upcoming edition of The Lancet.


Infectious complications and associated mortality are a major concern in acute pancreatitis. Around a fifth of patients with this disease have necrotising pancreatitis, which has a 10-30% mortality rate largely due to infectious complications. These complications are thought to start with overgrowth of small-bowel bacteria. Researchers have previously suggested that prophylaxis using strains of probiotic (‘good’ bacteria) might prevent infectious complications by reducing this small-bowel bacterial overgrowth -- thereby restoring gastrointestinal barrier function, and modulating the immune system.


Professor Hein Gooszen, University Medical Center Utrecht, Netherlands, and colleagues, did a randomised, double-blind, placebo controlled trial of 296 patients with predicted severe acute pancreatitis -- 152 in the probiotics group, and 144 in the placebo group. The patients in each group were similar in terms of characteristics and disease severity. Each of the patients was randomly assigned within 72 hours of onset of symptoms to receive a multispecies probiotic preparation* or placebo, administered enterally** twice daily for 28 days. All were monitored for the occurrence of infectious complications -- ie, infected pancreatic necrosis, bacteraemia, pneumonia, urosepsis, or infected ascites*** -- during both admission and 90 day-follow-up.


They found that the proportions of patients having infectious complications was similar in both groups -- 46 patients (30%) in the probiotics group and 41 (28%) in the placebo group. However, in the probiotics group many more of these patients died -- 24 (16%), versus nine (6%) in the placebo group. Nine patients in the probiotics group developed bowel ischaemia -- eight with fatal outcome -- compared with none in the placebo group.


The authors say: Our findings show that probiotics should not be administered routinely in patients with predicted severe acute pancreatitis, and that the particular composition used here should be banned for the present indication. Whether other combinations of strains might have resulted in different results is debatable, but, until the underlying mechanism is actually revealed, administration of probiotics in patients with predicted severe acute pancreatitis must be regarded as unsafe.


Most importantly, probiotics can no longer be considered to be harmless adjuncts to enteral nutrition, especially in critically ill patients or patients at risk for non-occlusive mesenteric ischaemia.





Advertise in this space for $10 per month. Contact us today.


Related Latest Research News


Subscribe to Latest Research Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)